George J Mulligan

Citado por

	Total	Desde 2020
Citas	11761	2565
Índice h	40	23
Índice i10	49	35

640

320

160

480

19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202534 40 42 65 177 293 304 320 290 265 261 255 255 253 233 275 330 375 492 492 601 633 513 526 569 577 577 571 616 518 409 406 41

Acceso público

Ver todo

10 artículos

0 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Barbara BryantConstellation PharmaceuticalsDirección de correo verificada de constellationpharma.com
Wee Joo ChngCancer Science Institute of SingaporeDirección de correo verificada de nus.edu.sg
Tyler JacksDirección de correo verificada de breakthroughcancer.org
Hartmut GoldschmidtUniversitätsklinikum HeidelbergDirección de correo verificada de med.uni-heidelberg.de
Peter Leif BergsagelMayo Clinic in ArizonaDirección de correo verificada de mayo.edu
R KuiperDepartment of hematology, Erasmus Medical Center, Rotterdam, The NetherlandsDirección de correo verificada de Skylinedx.com
Erik H. van BeersSanquin Diagnostic Services B.V.Dirección de correo verificada de sanquin.nl
Bart O. WilliamsVan Andel Research InstituteDirección de correo verificada de vai.org
John D. Shaughnessy, JrUAMSDirección de correo verificada de uams.edu
Gareth MorganNYUDirección de correo verificada de nyulangone.org
Vincent RajkumarMayo ClinicDirección de correo verificada de mayo.edu
Rafael Fonseca M.D.Mayo Clinic in Arizona, Professor of MedicineDirección de correo verificada de mayo.edu
Constantine MitsiadesBroad Institute Of MIT & Harvard, Dana-Farber Cancer InstituteDirección de correo verificada de broadinstitute.org
Shaji Kunnathu KumarMayo ClinicDirección de correo verificada de mayo.edu
R Donald Harvey, PharmD, BCOP, FC...Emory University School of Medicine and Winship Cancer InstituteDirección de correo verificada de emory.edu
Laura AttardiProfessor of Radiation Oncology and Genetics, Stanford UniversityDirección de correo verificada de stanford.edu
A. keith stewartuniversity health networkDirección de correo verificada de uhn.ca
Robert Z. OrlowskiThe University of Texas MD Anderson Cancer CenterDirección de correo verificada de mdanderson.org
Shizuo MukaiAssociate Professor of OphthalmologyDirección de correo verificada de meei.harvard.edu
Julio HajdenbergUF Health Cancer Center at Orlando HealthDirección de correo verificada de orlandohealth.com

Seguir

George J Mulligan

Multiple Myeloma Research Foundation

Dirección de correo verificada de themmrf.org

Oncology Translational Medicine Rare Diseases


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ... Cancer cell 12 (2), 131-144, 2007	1251	2007
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models L Shi, G Campbell, WD Jones, F Campagne, Z Wen, SJ Walker, Z Su, ... Nature biotechnology 28 (8), 827-838, 2010	892	2010
SR proteins and splicing control 1569 JL Manley, R Tacke, BLM Hogan, KL Friedman, JD Diller, BM Ferguson, ... Genes Dev 10, 1569-1579, 1996	874	1996
A subset of p53-deficient embryos exhibit exencephaly VP Sah, LD Attardi, GJ Mulligan, BO Williams, RT Bronson, T Jacks Nature genetics 10 (2), 175-180, 1995	733	1995
Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization J Sage, GJ Mulligan, LD Attardi, A Miller, SQ Chen, B Williams, ... Genes & development 14 (23), 3037-3050, 2000	726	2000
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma S Kumar, I Flinn, PG Richardson, P Hari, N Callander, SJ Noga, ... Blood, The Journal of the American Society of Hematology 119 (19), 4375-4382, 2012	583	2012
Shared role of the pRB-related p130 and p107 proteins in limb development. D Cobrinik, MH Lee, G Hannon, G Mulligan, RT Bronson, N Dyson, ... Genes & development 10 (13), 1633-1644, 1996	565	1996
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib G Mulligan, C Mitsiades, B Bryant, F Zhan, WJ Chng, S Roels, E Koenig, ... Blood 109 (8), 3177-3188, 2007	478	2007
Targeted disruption of p107: functional overlap between p107 and Rb. MH Lee, BO Williams, G Mulligan, S Mukai, RT Bronson, N Dyson, ... Genes & development 10 (13), 1621-1632, 1996	460	1996
The retinoblastoma gene family: cousins with overlapping interests G Mulligan, T Jacks Trends in Genetics 14 (6), 223-229, 1998	424	1998
Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle. BG Novitch, GJ Mulligan, T Jacks, AB Lassar The Journal of cell biology 135 (2), 441-456, 1996	381	1996
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients A Broyl, D Hose, H Lokhorst, Y de Knegt, J Peeters, A Jauch, U Bertsch, ... Blood, The Journal of the American Society of Hematology 116 (14), 2543-2553, 2010	377	2010
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma WJ Chng, GF Huang, TH Chung, SB Ng, N Gonzalez-Paz, T Troska-Price, ... Leukemia 25 (6), 1026-1035, 2011	329	2011
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling WJ Chng, S Kumar, S VanWier, G Ahmann, T Price-Troska, K Henderson, ... Cancer research 67 (7), 2982-2989, 2007	326	2007
A gene expression signature for high-risk multiple myeloma R Kuiper, A Broyl, Y de Knegt, MH Van Vliet, EH Van Beers, ... Leukemia 26 (11), 2406-2413, 2012	303	2012
Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma JJ Shah, AJ Jakubowiak, OA O'Connor, RZ Orlowski, RD Harvey, ... Clinical Cancer Research 22 (1), 34-43, 2016	193	2016
Polypyrimidine tract binding protein interacts with sequences involved in alternative splicing of beta-tropomyosin pre-mRNA. GJ Mulligan, W Guo, S Wormsley, DM Helfman Journal of Biological Chemistry 267 (35), 25480-25487, 1992	192	1992
Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non–germinal center B-cell–like diffuse large B-cell lymphoma JP Leonard, KS Kolibaba, JA Reeves, A Tulpule, IW Flinn, T Kolevska, ... Journal of Clinical Oncology 35 (31), 3538-3546, 2017	189	2017
Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors J Sarantopoulos, GI Shapiro, RB Cohen, JW Clark, JS Kauh, GJ Weiss, ... Clinical Cancer Research 22 (4), 847-857, 2016	180	2016
The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition WJ Chng, E Braggio, G Mulligan, B Bryant, E Remstein, R Valdez, ... Blood, The Journal of the American Society of Hematology 111 (3), 1603-1609, 2008	147	2008

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores